Portal de Periódicos da CAPES

Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation

2011; American College of Physicians; Volume: 154; Issue: 8 Linguagem: Inglês

10.7326/0003-4819-154-8-201104190-00012

1539-3704

Alan M. Berg,

Pharmaceutical Economics and Policy

Letters19 April 2011Dabigatran Compared With Warfarin for Stroke Prevention in Atrial FibrillationAlan M. Berg, MDAlan M. Berg, MDFrom Margolis Rheumatology Associates–University of Pittsburgh Medical Center, Pittsburgh, PA 15215.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-154-8-201104190-00012 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In their recent article on the cost-effectiveness of dabigatran versus warfarin, Freeman and colleagues (1) did not account for some of the highest costs associated with warfarin administration. Each time that prothrombin time is measured, the logistics involved cost money. Patients must travel to the laboratory to have blood drawn, or family members must take them. If patients are homebound, the cost of visiting nurses is high.The authors also did not account for the costs of prothrombin time measurement for physicians, patients, and caregivers. For example, when one of my patients undergoes measurement of prothrombin time, ...Reference1. Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154:1-11. [PMID: 21041570] LinkGoogle Scholar Author, Article, and Disclosure InformationAuthors: Alan M. Berg, MDAffiliations: From Margolis Rheumatology Associates–University of Pittsburgh Medical Center, Pittsburgh, PA 15215.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation James V. Freeman , Ruo P. Zhu , Douglas K. Owens , Alan M. Garber , David W. Hutton , Alan S. Go , Paul J. Wang , and Mintu P. Turakhia Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation David B. Edwards and John Silverberg Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation James V. Freeman and Mintu P. Turakhia Metrics Cited byThe caregiver role in thromboprophylaxis management in atrial fibrillation: A literature reviewEstimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillationMedical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials 19 April 2011Volume 154, Issue 8Page: 570KeywordsCommunication in health careConflicts of interestDrug administrationDrugsGamesHealth careNursesProthrombin timeResearch laboratoriesStroke ePublished: 19 April 2011 Issue Published: 19 April 2011 Copyright & PermissionsCopyright © 2011 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...